New Infertility Center of St Louis – FDA 483, Apr 22, 2026
An FDA inspection of New Infertility Center of St Louis in Chesterfield, MO, revealed critical deficiencies in their Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) program. The firm failed to adequately screen oocyte donors for communicable disease risks, improperly determined donor eligibility despite incomplete screening, and maintained inadequate procedures for ensuring compliance with donor eligibility requirements. These issues indicate a significant risk regarding the safety and suitability of donated oocytes.
- Person
ID · 11ecdbb7-f77d-4847-bb2d-9dc3b38f848f
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.